Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display

被引:33
作者
Cheng, KH
Ponte, JF
Thiagalingam, S
机构
[1] Boston Univ, Sch Med, Genet Program, Dept Med,Pulm Ctr, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Genet Program, Canc Res Ctr, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA
[4] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA
关键词
D O I
10.1158/0008-5472.CAN-03-2688
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To address the challenge of identifying related members of a large family of genes, their variants and their patterns of expression, we have developed a novel technique known as targeted expressed gene display. Here, we demonstrate the general application of this technique by analyzing the SMAD genes and report that the loss of SMAD8 expression is associated with multiple types of cancers, including 31% of both breast and colon cancers. Epigenetic silencing of SMAD8 expression by DNA hypermethylation in cancers directly correlates with loss of SMAD8 expression. The SMAD8 alteration in a third of breast and colon cancers makes it a significant novel tumor marker as well as a potential therapeutic target. The utility of targeted expressed gene display for the analysis of highly homologous gene families as demonstrated by its application to the SMAD genes suggests that it is an efficient tool for the identification of novel members, simultaneous analysis of differential expression patterns, and initial discovery of alterations of expressed genes.
引用
收藏
页码:1639 / 1646
页数:8
相关论文
共 43 条
[1]   T beta RI phosphorylation of Smad2 on Ser(465) and Ser(467) is required for Smad2-Smad4 complex formation and signaling [J].
Abdollah, S ;
MaciasSilva, M ;
Tsukazaki, T ;
Hayashi, H ;
Attisano, L ;
Wrana, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (44) :27678-27685
[2]   Smads as transcriptional co-modulators [J].
Attisano, L ;
Wrana, JL .
CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (02) :235-243
[3]   Tying it all together: Epigenetics, genetics, cell cycle, and cancer [J].
Baylin, SB .
SCIENCE, 1997, 277 (5334) :1948-1949
[4]  
BOSCH I, 2000, NUCLEIC ACIDS RES, V28, P27
[5]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[6]   Clinical course and prognostic factors following bone recurrence from breast cancer [J].
Coleman, RE ;
Smith, P ;
Rubens, RD .
BRITISH JOURNAL OF CANCER, 1998, 77 (02) :336-340
[7]   Role of transforming growth factor-β signaling in cancer [J].
de Caestecker, MP ;
Piek, E ;
Roberts, AB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (17) :1388-1402
[8]   MADR2 maps to 18q21 and encodes a TGF beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma [J].
Eppert, K ;
Scherer, SW ;
Ozcelik, H ;
Pirone, R ;
Hoodless, P ;
Kim, H ;
Tsui, LC ;
Bapat, B ;
Gallinger, S ;
Andrulis, IL ;
Thomsen, GH ;
Wrana, JL ;
Attisano, L .
CELL, 1996, 86 (04) :543-552
[9]   The MAD-related protein Smad7 associates with the TGF beta receptor and functions as an antagonist of TGF beta signaling [J].
Hayashi, H ;
Abdollah, S ;
Qiu, YB ;
Cai, JX ;
Xu, YY ;
Grinnell, BW ;
Richardson, MA ;
Topper, JN ;
Gimbrone, MA ;
Wrana, JL ;
Falb, D .
CELL, 1997, 89 (07) :1165-1173
[10]   Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands [J].
Herman, JG ;
Graff, JR ;
Myohanen, S ;
Nelkin, BD ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9821-9826